Autolus Therapeutics plc - American Depositary Share (AUTL): Price and Financial Metrics
AUTL Price/Volume Stats
| Current price | $2.29 | 52-week high | $7.45 |
| Prev. close | $2.24 | 52-week low | $2.20 |
| Day low | $2.20 | Volume | 2,614,100 |
| Day high | $2.35 | Avg. volume | 1,492,159 |
| 50-day MA | $3.43 | Dividend yield | N/A |
| 200-day MA | $4.10 | Market Cap | 609.36M |
AUTL Stock Price Chart Interactive Chart >
Autolus Therapeutics plc - American Depositary Share (AUTL) Company Bio
Autolus Therapeutics is developing a pipeline of advanced programmable T cell treatment candidates for blood and solid tumor cancers. Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I), or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma. The company is based in London, England.
AUTL Price Returns
| 1-mo | -19.37% |
| 3-mo | -38.61% |
| 6-mo | -38.44% |
| 1-year | -59.68% |
| 3-year | -56.05% |
| 5-year | -83.11% |
| YTD | -64.44% |
| 2023 | 238.95% |
| 2022 | -63.39% |
| 2021 | -41.95% |
| 2020 | -32.27% |
| 2019 | -59.81% |
Loading social stream, please wait...